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аннотация
В обзоре проанализированы данные о роли хитиназоподобных белков (CLp), принадлежащих к се-
мейству белков, содержащих Glyco_18 домен и не обладающих ферментативной активностью, при 
различных злокачественных новообразованиях. У человека идентифицировано 3 таких белка: YKL-40 
(CHI3L1), YKL-39 (CHI3L2) и стабилин-связывающий CLp (SI-CLp). Хитиназоподобные белки, продуци-
руемые различными типами клеток, в том числе опухолевыми, проявляют активность как цитокины и 
ростовые факторы, а также они вовлечены в процессы воспаления. Высокий уровень CLp определяется 
в циркулирующей крови при воспалительных заболеваниях и разных локализациях злокачественных 
опухолей. Освещены данные о ключевых функциях CLp в физиологических и патологических условиях. 
Проанализированы сведения о вовлечении CLp в процессы инвазии, метастазирования, ангиогенеза, 
их связи с опухолевой прогрессией. Представлены собственные результаты, подтверждающие пер-
спективность разработки прогностических и предсказательных маркеров на основе CLp при злокаче-
ственных новообразованиях.
Ключевые слова: хитиназоподобные белки, CLP, YKL-30, YKL-40, SI-CLP, 
злокачественные новообразования, опухолевая прогрессия.
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Abstract
In the present review we collected the main studies regarding the role of chitinase-like proteins (CLps), 
belonging to the family of Glyco_18 domain-containing proteins, in different cancers. In humans, 3 chitinase-
like proteins have been identified: YKL-40 (CHI3L1), YKL-39 (CHI3L2) and stabilin-1-interacting chitinase-like 
protein (SI-CLp). CLps are produced by several types of cells and combine the properties of cytokines and 
growth factors. The high levels of CLps were identified in the circulation of the patients with inflammatory 
diseases and various types of tumors. We highlighted the main known functions of CLps in normal and 
pathological conditions, their contribution to metastasis development, angiogenesis, invasion and other 
processes in cancer, the correlation of the levels of CLps with tumour progression. our data also contribute 
to the understanding of question how CLp could be useful for cancer patient benefit. 
Keywords: chitinase-like proteins, CLP, YKL-30, YKL-40, SI-CLP, cancer, tumor progression.
Common features of CLPs family
Chitinase-like proteins (CLPs) are structurally re-
semble chitinases that belong to a group of proteins, 
which are widely expressed in nature, and distributed 
in a wide range of organisms, including mammals, 
bacteria, plants, insects, viruses. Proteins with chi-
tinase activity represent evolutionary ancient enzymes 
responsible for degradation of chitin, which is the 
second most abundant natural compound [1].
Mammalian chitinases and CLPs belong to glyco-
syl hydrolase family 18 (GH18) [2] due to presence of 
highly conserved Glyco_18 domain, responsible for 
sugar-binding, and catalytic site, which is essential 
for hydrolysis of chitin. The prehistoric purpose of 
GH18 existence is the degradation of complex sugar 
compounds, such as cellulose or chitin, via disruption 
of strong covalent or glycosylic bonds in polysaccha-
ridic chains that compose polymer molecules. There 
are only two mammalian chitinases identified as func-
tionally active enzymes, which are known as Acidic 
Mammalian Chitinase (AMCase) and Chitotriosidase 
(CHIT1) and they are both expressed in human [3, 4]. 
AMCase was firstly revealed in macrophages from pa-
tients with Gaucher disease [5]. The source of secreted 
chitotriosidase is abnormal lipid-laden macrophages 
that can be classified as a variation of alternatively 
activated macrophages, expressing CD68, CD14, 
HLA class II, CD163, CCL18 and IL-1-receptor an-
tagonist, but not CD11b, CD40 and pro-inflammatory 
cytokines [6].
Chitinase-lake proteins predominantly contain 
Glyco-18 domain but not catalytic site (glycosyl 
hydrolase function). These proteins are also known 
as enzymatically inactive chi-lectins [2]. There are 4 
known mammalian CLPs: YKL-40 (CHI3L1), YKL-
39 (CHI3L2), stabilin-1-interacting chitinase-like 
protein (SI-CLP), and YM1/YM2 [7-10]. YM1/YM2 
proteins are only found in rodents. YKL-39 is only 
present in humans and absent in rodents. All CLPs 
have specific characteristics in carbohydrate binding 
site. The binding region is located in (α/β)8 TIM-barrel 
domain, which allows CLPs to interact with chitin oli-
gosaccharides with high affinity [10, 11]. It is crucial 
to be aware about the binding characteristics of CLP, 
because it allows prediction of the binding partners 
and, therefore, prediction of biological functions re-
lated to that binding.
YKL-39 is known to bind to chitooligosaccha-
rides (GlcNac)5 and (GlcNac)6 [11, 12], that was 
demonstrated by glycan array screening, intrinsic 
tryptophan fluorescence and isothermal titration 
calorimetry (ITC). There are more binding targets 
known for YKL-40; it can bind to type I collagen that 
was revealed by affinity chromatography and surface 
plasmon resonance [13], to chitooligosaccharides, that 
shown in protein X-ray crystallography assay [14]; 
(GlcNac)5 and (GlcNac)4 that revealed by the Western 
blot [15] and heparin demonstrated by heparin affinity 
and HPLC chromatography [16]. ITC analysis showed 
that SI-CLP can bind to galactosamine, glucosamine, 
chitooligosacharide, (GlcNac)4, ribose and mannose 
[17]. It was demonstrated by surface plasmon reso-
nance analysis that YM1 can bind to glucosamine, 
galactosamine and glucosamine polymers [18].
The main sources and functions of CLPs
The secretion of chitinase-like proteins was 
found in macrophages, neutrophils, epithelial 
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cells, chondrocytes and synovial cells, vascular 
smooth muscle cells as well as tumor cells (includ-
ing breast, colon, kidney, lung, ovarian, prostate, 
uterine, osteosarcoma, glioblastoma) and their 
expression was regulated by various cytokines 
and hormones [1, 12].
YKL-39 is predominantly secreted by chon-
drocytes and synoviocytes and is recognized as a 
biochemical marker for the activation of chondrocytes 
and progression of osteoarthritis in humans [19].
YKL-40 is secreted by chondrocytes, synoviocytes, 
differentiated vascular smooth muscle cells, fibroblast-
like synovial cells, by macrophages in the atheroscle-
rotic plaque, tumor cells in many cancers [1, 20, 21]. In 
vivo, YKL-40 expression was found in places with 
intensive tissue remodeling [1]. YKL-40 regulates 
cell proliferation, migration, adhesion, macrophage 
differentiation, as well as extracellular matrix assembly 
and correlates with an elevated level of YKL-40 in 
chronic inflammation and connective tissue turnover 
[1, 22]. YKL-40 promotes the proliferation of chondro-
cytes and fibroblasts, migration and reorganization of 
vascular endothelial cells as well as inflammation and 
remodeling of extracellular matrix [1, 16]. It induces 
the migration of vascular smooth muscle cells (VSMC) 
[16] and promotes the growth of human synovial cells, 
skin and fibroblasts. High YKL-40 level was detected 
in serum of patients with rheumatoid arthritis (RA) and 
in patients with type 2 diabetes [1].
SI-CLP expression was found in various tumor cell 
lines, Raji cells, Jurkat cells, as well as in CD3+ T-cells, 
in the synovial fluid of patients with osteoarthritis or 
rheumatoid arthritis [17].
Expression of YKL-40 mRNA in human monocyte 
was strongly upregulated by IFN-gamma, and inhibited 
by IL-4 and dexamethasone [9]. There are also 
evidences that YKL-40 is secreted by macrophages 
during the late stages of differentiation. YKL-40 
gene expression was up-regulated in monocytes 
stimulated with granulocyte-macrophage colony-
stimulating factor, in colony-stimulating factor 
stimulated monocytes and in lipopolysaccharide 
stimulated monocytes [23, 24].
For YKL-39, no specific effects of IFN-
gamma, IL-4 or dexamethasone were detected, 
but YKL-39 was upregulated in macrophages 
differentiated in the presence of IL-4+TGF-beta, 
but not IL-4 alone [25].
Human macrophages produce also SI-CLP and 
its expression is induced by Th2 cytokine IL-4 and 
glucocorticoid dexamethasone [9]. In vivo, high 
amounts of SI-CLP were detected in macrophages 
from bronchoalveolar lavage of patients with chronic 
airway inflammation [17].
In macrophages, SI-CLP is primarily localized 
in the secretory lysosomes. Kzhyshkowska et al. 
demonstrated that the intracellular sorting of SI-CLP 
in alternatively activated macrophages was mediated 
by the scavenger receptor stabilin-1, which was 
specifically expressed on subpopulations of tissue 
macrophages and sinusoidal endothelial cells in liver, 
spleen, lymph node and bone marrow. Stabilin-1 
recognized SI-CLP in trans-Golgi network and 
delivered it to the late endosomes and consequently 
into Lamp1-positive and CD63-positive lysosomes 
[9]. The pattern of intracellular YKL-39 distribution 
was similar to the pattern demonstrated for SI-CLP 
suggesting that YKL-39 can be secreted by the 
lysosomal secretory pathway. Endogenous YKL-39 
was found in the trans-Golgi network, where it was 
partially co-localized with stabilin-1. Using GST pull-
down assay we showed that stabilin-1 can act as an 
intracellular sorting receptor for YKL-39 [25].
The role of CLPs in angiogenesis 
and chemotaxis
Among all chitinases and chitinase-like proteins, 
the pro-angiogenic activity and function of YKL-40 
in various types of cancer progression were well 
studied. Angiogenic properties of YKL-40 in cancer 
development were demonstrated in breast and brain 
cancers where the expression level of YKL-40 was 
associated with tumor vascular formation [26, 27]. 
Immunohistochemical analysis of human breast cancer 
demonstrated a correlation between blood vessel 
density and YKL-40 protein expression [26]. In mouse 
model of breast cancer, YKL-40 was demonstrated to 
promote tumor growth by supporting angiogenesis. 
In mouse model of melanoma and glioblastoma, the 
inhibiting effect of anti-YKL-40 monoclonal antibody 
on tumor growth was shown [28, 29]. It was revealed 
that YKL-40 can facilitate tumor angiogenesis by 
interacting with syndecan-1 on endothelial cells and 
metastasis by stimulating production of MMP-9, CCL2 
and CXCL2 [30].
Several studies on in vitro tube formation and 
endothelial cell migration have demonstrated that 
YKL-40 has stimulating effect on the endothelial cells 
that is similar to the effect of endothelial growth factor 
(VEGF) [27]. YKL-40-heparin interaction promotes the 
interaction with syndecan-1 and αvβ3 integrin, leading 
to activation of the ERK1/2 pathway and stimulation of 
VEGF [26, 27]. In glioblastoma, transient suppression 
of VEGF substantially increased YKL-40 expression 
and promoted tumor angiogenesis [31]. Anti-VEGF 
neutralizing antibody did not improve HMVECs tube 
formation and migration induced by YKL-40, thus 
confirming that pro-angiogenic effects of YKL-40 on 
HMVECs were not affected by VEGF [26].
Chitinase-like proteins can influence chemotactic 
activity of various cells directly or indirectly. Using an 
in vitro microchemotaxis transwell system model, Nio 
et al. demonstrated that YM1 acted as a chemotactic 
factor for eosinophils, T-lymphocytes and bone marrow 
cells [32]. YKL-40 was shown to affect chemotaxis of 
VSMC [16], THP-1 cells [33] and bronchial smooth 
muscle cells [34]. For THP-1 and VSMC cells, purified 
YKL-40 induced chemotaxis directly. In contrary, for 
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bronchial smooth muscle cells and SW480, YKL-40 
enhanced secreted levels of IL-8, thus providing a 
chemotactic effect.
YKL-40 significantly increased the migration 
and invasion ability of CL1-1 NSCLC (non-small 
cell lung cancer) cell lines by regulating EMT 
(Epithelial Mesenchimal Transition) genes. In YKL-40 
overexpressed cell line, the expression of E-cadherin, 
a marker of epithelial cells, was significantly lower; 
and the expression of markers of mesenchymal cells 
(N-cadherin, Vimentin) was significantly higher as 
well as other EMT regulators (Snail, Slug, and Twist) 
[35]. Moreover, inhibition of YKL-40 reduced the 
tube formation in vitro and suppressed tumor growth, 
angiogenesis, and progression of brain tumors [28].
Analysis of biological functions of YKL-39 
demonstrated that it is unique that CLP combines 
monocyte attracting and pro-angiogenic activities, 
which essential for tumor progression [25]. The 
angiogenesis assay showed that recombinant YKL-
39 induced tube formation of HUVEC cells 6 times 
higher than that observed in the negative control group, 
and this induction was more than 60% of positive 
control. The chemotactic effect of YKL-39 on primary 
monocytes was approximately 2 times higher after 1 
h and more than 5 times higher after 3 h compared to 
control, and this effect was comparable with the effect 
of MCP-1/CCL2 chemokines [25].
CLPs in cancer
YKL-40 is expressed by several types of solid 
tumors including breast, colon, lung, kidney, head 
and neck, liver, bladder, prostate, stomach, ovary, 
pancreas, osteosarcoma, thyroid, glioblastoma and 
endometrial cancers. Microarray analysis identified 
YKL-40 gene as one of the most overexpressed genes 
in glioblastoma, papillary thyroid carcinoma, and 
chondrosarcoma [36]. YKL-40 protein expression 
was found in biopsies of glioblastomas, breast cancer 
and colon cancer. In vitro YKL-40 was secreted by 
the following human cancer cell lines: osteosarcoma, 
glioblastoma, colon cancer, ovarian cancer, prostate 
cancer and malignant melanoma [37]. YKL-40 
protein expression was found in tumor associated 
macrophages (TAM) in patients with melanoma [37]. 
YKL-40 protein was not expressed in small cell lung 
cancer cells, but YKL-40 mRNA expression was 
elevated in TAM [36].
In tumors, YKL-40 may contribute to the 
proliferation and differentiation of malignant cells, 
protect the cancer cells from apoptosis, stimulate 
angiogenesis, and regulate extracellular tissue 
remodeling [23]. In non-small cell lung cancer, YKL-
40 may also regulate (PI3K)/AKT/mTOR pathway, 
which is related with cell transformation, tumor 
survival, invasion and metastasis, and is a central 
feature of EMT [23]. In breast cancer, YKL-40 levels 
were inversely correlated with expression of GATA3 
and E-cadherin, which regulate cell-cell contacts and 
act as tumor inhibitors [37]. The high risk of tumor 
progression may be explained either by the fact that 
cancer cells and TAM produce YKL-40, or that chronic 
inflammation causes both elevated plasma YKL-40 
and cancer.
In our study we showed that the elevated levels 
of YKL-39 expression in tumors after neoadjuvant 
chemotherapy (NAC) were associated with increased 
risk of distant metastasis and poor response to NAC 
in patients with nonspecific invasive breast carcinoma 
[25]. Moreover, in the study of gene expression of 
M2 macrophage markers (YKL-39 and CCL18) we 
found that in breast cancer patients, who received 
anthracycline-containing NAC, the absence of 
clinical response was associated with the presence of 
M2+ macrophage phenotype (YKL-39-CCL18 + or 
YKL-39 + CCL18-) [38]. Kavsan et al. reported the 
increased expression of CHI3L2 gene in glioblastoma 
[39]. However, there is still insufficient data on the 
association of both YKL-39 gene and protein level 
with tumor progression, and no data on SI-CLP in 
tumor progression are available. 
YKL-40 is a marker of late stages of cancer
Elevated plasma YKL-40 was found in patients 
with metastatic pancreatic and ovarian adenocarcinoma 
[36]. In patients with gastric cancer, serum levels of 
YKL-40 were significantly higher compared to those 
observed in healthy population, and the increased 
YKL-40 level indicated more aggressive phenotype 
of tumor [40]. Plasma YKL-40 level was elevated in 
approximately 80% of patients with metastatic renal 
cell carcinoma [37]. Dupont et al. showed that serum 
YKL-40 was upregulated in 65% of patients with 
stage I and II ovarian cancer in contrast to 74-91% of 
patients with stage III and IV cancer [41]. In patients 
with small cell lung cancer, the highest percentage of 
the patients who had elevated serum YKL-40 level 
was associated with advanced disease compared to 
local one. More than 80% of patients with metastatic 
renal cell cancer and more that 40% of patients 
with metastatic malignant melanoma and metastatic 
prostate cancer had also elevated serum YKL-40. In 
patients with glioblastoma, the serum YKL-40 level 
was higher in patients with glioblastoma multiforme 
compared to patients with lower grade gliomas [23]. 
In breast cancer, increased serum levels of YKL-40 
were found more frequently in patients with metastatic 
cancer compared to patients with early cancer [23]. 
YKL-40 is associated with cancer aggressiveness. It 
was reported that not serum but urine YKL-40 level 
can be helpful in the diagnosis of bladder cancer in 
the assistance to BTA protein. Urine YKL-40 level 
was significantly higher in all invasive subgroups 
(T1, T2–T4, and T1–T4) compared to low stage (Ta) 
and can help determine treatment regimen in early 
invasive stages [42].
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YKL-40 as an independent 
marker of tumor progression
Serum YKL-40 as a prognostic marker was 
independent of serum carcinoembryonic antigen in 
patients with colorectal cancer, of serum CA-125 and 
CA15-3 in patients with ovarian cancer, of estrogen 
receptor status, KRAS mutation status, of serum HER2 
in patients with metastatic breast cancer, of serum 
prostate-specific antigen in patients with metastatic 
prostate cancer, and of serum lactate dehydrogenase 
in patients with small cell lung cancer or metastatic 
malignant melanoma and of clinical parameters (i.e., 
age, performance status, tumor stage, histology), 
indicating that serum YKL-40 reflects other pathogenic 
aspects of tumor progression than these tumor markers 
[23]. Plasma YKL-40 in pre-treatment patients was 
shown to be an independent prognostic biomarker 
of short overall survival both at time of first cancer 
diagnosis and at time of relapse in patients with 
different types of adenocarcinoma (breast, colorectal, 
endometrial, non-small cell lung, ovary, cervix and 
prostate), in patients with head and neck and cervix 
squamous cell carcinoma [36]. 
In gastric cancer, high YKL-40 protein level was 
an independent biomarker of short survival and was 
associated with tumor invasion, lymph node metastasis 
[43]. In patients with localized or advanced small 
cell lung carcinoma, high plasma YKL-40 levels 
before chemotherapy independently predicted short 
survival [44]. Pre-treatment plasma and serum level 
of YKL-40 was an independent prognostic biomarker 
in patients with metastatic prostate cancer [36]. Serum 
level of YKL-40 is also an independent marker for the 
aggressiveness of metastatic breast cancer [1]. High 
plasma YKL-40 in patients with metastatic colorectal 
cancer before treatment was associated with short 
progression free survival and short overall survival, 
independently of KRAS status [45]. However, serum 
concentrations of YKL-40 do not show high sensitivity 
for early diagnostics of cancer and YKL-40 cannot 
be used as a single screening marker for diagnosis of 
cancer [1, 23]. 
Elevated YKL-40 level may serve 
as a useful potential prognostic biomarker 
for cancer patients
Serum levels of YKL-40 are indicative for the poor 
prognosis of metastatic process. Increased plasma 
concentration of YKL-40 is related to poor prognosis 
and shorter survival in patients with breast cancer, 
gastric cancer, ovarian cancer, colorectal carcinoma, 
metastatic prostate carcinoma, melanoma and many 
other cancers. High plasma YKL-40 levels predicted 
an absolute 10-year risk of gastrointestinal cancer in 
patients who were >70 years and smokers [46].
For advanced pancreatic cancer it was shown that 
the combination of plasma YKL-40, CA-19-9 and 
osteopontin was more sensitive compared to CA-19-9 
alone [47]. High plasma YKL-40 was a predictor 
of chemoresistance in patients with ovarian cancer 
and breast cancer during treatment [36]. In recurrent 
breast cancer, high serum YKL-40 was associated with 
metastasis and high tumor grade and was elevated 
mostly in case of visceral and bone metastasis and 
less in case of lymph nodes metastasis. Moreover, the 
highest serum YKL-40 levels were found in patients 
with more than two different metastatic sites [23].
It was found that colorectal cancer patients with 
elevated serum YKL-40 after surgery had significantly 
shorter recurrence-free period and overall survival than 
patients with normal serum YKL-40, indicating that 
YKL-40 may be useful for the monitoring of cancer 
patients [23].
Conclusion remarks
In the present review we shortly highlighted the 
main features of CLPs, their key function and their 
ability to contribute to tumor progression. Nowadays 
we have clear evidences about the correlation with 
survival, invasion, metastasis etc. only for YKL-40 
protein. There are a lot of studies related to the YKL-40 
serum levels with cancer aggressiveness and disease 
progression. However, many fundamental aspects 
regarding the function, mechanisms of action and 
regulation of YKL-40 as well as YKL-39 and SI-CLP 
in cancer remain unclear. Problems regarding the direct 
or indirect contribution of YKL-39 and SI-CLP to 
tumor progression remain to be solved. 
Future translational researches combining basic and 
clinical basis are needed and should give the answers 
on the main questions: “Are CLPs useful clinical 
biomarker for patients with cancer?” and “Can CLPs 
potentially become new targets for cancer therapy?”.
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